Medicare GLP-1 Bridge: $50 Weight-Loss Drugs (2026)

The Honest Answer

PIN IT

The Medicare GLP-1 Bridge does not repeal the law that keeps weight-loss drugs out of Medicare Part D — that rule is still on the books, and nothing about it changed in 2026.

What changed is a temporary layer on top of it: a demonstration running July 1, 2026 through December 31, 2027, with its own rules, its own paperwork, and its own flat price.

CMS calls the Bridge a short-term demonstration, and the details decide everything: which version of which drug, which BMI tier, and whether your plan already covering a GLP-1 locks you out.

Bridge Snapshot

Here is the whole program on one screen.

Two names need a beat. Foundayo (orforglipron) is Eli Lilly’s once-daily GLP-1 tablet, FDA-approved April 1, 2026 — the first GLP-1 pill for weight loss. And the Zepbound entry means exactly what it says: Medicare’s official fact sheet spells out that single-dose pens and vials are not covered, KwikPen only.

Who Qualifies: All Four, No Exceptions

Medicare’s fact sheet lists four requirements for the Medicare GLP-1 Bridge, and you need every one of them.

1. You have Part D drug coverage. A standalone drug plan or a Medicare Advantage plan with drug coverage both work; a few plan types (private fee-for-service, cost contract plans, PACE) sit outside the program.
2. You cannot already get a GLP-1 through your plan. If your plan covers one for you for any reason, the Bridge is closed to you — more on this below.
3. You do not have type 2 diabetes, moderate-to-severe sleep apnea, or MASH (a serious form of fatty liver disease). Those conditions have their own coverage lanes.
4. You are 18 or older and fit one of three BMI tiers, below.

Illustrative examples — not real patients — to make the tiers concrete:

• Say Margaret, 68, has a BMI of 31 and takes two blood-pressure medicines that are not controlling it. She fits the second tier.
• Say Frank, 72, has a BMI of 28 and prediabetes flagged at his last physical. That is the third tier.
• Say Diane, 70, has a BMI of 33 and is otherwise healthy. She does not qualify — between 30 and 34.9 you need one of the listed conditions, and 35 is the only number that stands alone.

The second requirement catches people off guard because it runs backwards from how coverage usually works. If your plan already covers a GLP-1 for you — say Wegovy for heart protection after a heart attack — you are locked out of the Bridge.

That is by design: the Bridge is for people with no other Medicare route — and the plan pathway you already have counts toward your yearly out-of-pocket cap, which the Bridge never does.

How the Bridge Works (No Sign-Up)

There is no application, no enrollment window, and no membership card. The whole thing runs between your doctor, your pharmacy, and Medicare:

1. Your doctor decides a Bridge drug is appropriate and writes the prescription.
2. The prescription goes to your pharmacy, and the pharmacy needs your Medicare ID — Bridge claims run on your Medicare number, not your plan card.
3. Your doctor submits a prior-authorization request to a CMS central processor — Medicare directly, not your Part D plan.
4. You get a confirmation letter once the request is approved.
5. You pick up the prescription and pay $50.

Refills of the same drug do not need a new prior authorization, even if your dose changes; switching to a different Bridge drug starts a new request. If anything goes sideways, call 1-800-MEDICARE — the program bypasses your plan, so your plan’s customer service is the wrong door.

Drug by Drug: Covered or Not

GLP-1 is a drug class, not one Medicare answer, and the brand name on the bottle changes everything. Two names get full companion guides — does Medicare cover Ozempic for weight loss and does Medicare cover Wegovy — but here is the whole class in one table.

The row that generates the most mail is Ozempic: same molecule as Wegovy, but no FDA weight-loss label, so no 2026 pathway pays for it as a weight-loss prescription. The full Ozempic answer covers what to ask your doctor about instead.

The most expensive mistake is Zepbound. A prescription written for vials or single-dose pens will not process through the Bridge, full stop. If that is what you have, ask your doctor to rewrite it for the KwikPen before you get to the counter.

What the $50 Does and Does Not Do

The good news first: the $50 is flat — the same at every income and every dose, with no deductible to meet first. For drugs listing above $1,000 a month, that is a genuinely good deal.

Now the fine print, all of it from the Bridge operating outside Part D:

• It does not count toward your Part D deductible (up to $615 in 2026).
• It does not count toward the $2,100 out-of-pocket cap — yes, $2,100, not 2025’s $2,000; CMS indexed the cap up for 2026.
• Extra Help (the low-income subsidy) does not lower it.
• You cannot spread it out through the Medicare Prescription Payment Plan.
• Manufacturer coupons cannot be applied to it.

Say you start Wegovy through the Bridge in July 2026 and stay on through the end of 2027: eighteen fills at $50 is $900 total, and none of it moves you toward catastrophic coverage. If you also take expensive plan-covered medications, budget the two tracks separately.

How We Got Here: 2024 to 2026

The short version of a long two years:

• March 2024 — the FDA added a heart-protection use to Wegovy’s label, and CMS told Part D plans they could cover it for that use.
• November 2024 — a federal proposal to cover weight-loss drugs outright was floated. It was never finalized.
• December 2024 — Zepbound picked up a sleep-apnea use, opening a second plan-by-plan lane.
• November 2025 — the White House announced pricing deals with Novo Nordisk and Eli Lilly, and a $50 Medicare copay program was promised.
• April 1, 2026 — the FDA approved Foundayo (orforglipron), the first GLP-1 pill for weight loss.
• July 1, 2026 — CMS launched the Medicare GLP-1 Bridge, and $50 fills went live at pharmacies.

After 2027: Plan for the Cliff

The Medicare GLP-1 Bridge ends December 31, 2027, and there is no announced successor. A companion effort to build GLP-1 coverage into Part D itself — the BALANCE model’s Part D piece — has been indefinitely delayed, so do not count on a hand-off.

If you start a Bridge drug in 2026, you could be a year and a half into treatment when the program stops. Four practical moves: put the end date on your calendar; ask your doctor early what the plan is if the pathway disappears; use the fall 2027 open-enrollment window to compare plans; and treat any headline about an extension as unconfirmed until CMS says it.

Medicare vs Medicaid

Medicare and Medicaid are different programs with different rules, and this guide is about Medicare. On the Medicaid side, only about 13 states covered GLP-1s for obesity as of early 2026, per KFF’s tracking.

The awkward overlap is for people on both. If you are dual-eligible, Extra Help normally shrinks your drug costs to a few dollars — but it does not touch the Bridge’s $50. For someone used to $4 prescriptions, that is a real gap worth naming before the first fill.

FAQs

Quick answers on the Medicare GLP-1 Bridge:

The follow-up questions readers actually send.

1. When does the Medicare GLP-1 Bridge end?

The program is scheduled to end December 31, 2027, and it is a temporary demonstration rather than a permanent benefit. No defined pathway has been announced for 2028, so anyone starting one of these drugs should ask their doctor about a backup plan well before the deadline instead of assuming the copay simply continues.

2. Does the $50 copay count toward my Part D out-of-pocket cap?

The $50 sits completely outside Part D. It never counts toward your $615 maximum deductible or the $2,100 out-of-pocket cap for 2026, because the Medicare GLP-1 Bridge runs its own payment system. Eighteen months of fills adds up to $900, and none of that spending builds toward catastrophic coverage for the rest of your drugs.

3. Does the Medicare GLP-1 Bridge cover weight-loss drugs if I have type 2 diabetes?

People with type 2 diabetes are excluded from the Bridge, along with those who have moderate-to-severe sleep apnea or MASH fatty liver disease. That sounds harsh, but there is a reason: your regular Part D plan already covers GLP-1s like Ozempic and Mounjaro for diabetes, so you use that pathway instead.

4. Is there an income limit for the Bridge?

There is no income test in either direction. Everyone who qualifies for the Medicare GLP-1 Bridge pays the same flat $50 per month, whether they have Extra Help or a comfortable retirement. That cuts both ways: low-income subsidies do not reduce the copay, and higher earners are never charged a single penny more.

5. Which Zepbound products does the Medicare GLP-1 Bridge cover?

Only the Zepbound KwikPen qualifies. Single-dose pens and vials are explicitly left out, which trips up people who assume the Bridge applies to every version of a covered brand. If your prescription says vials, ask your doctor to rewrite it for the KwikPen before the pharmacy tries to run the claim.

6. How do I sign up for the $50 GLP-1 copay?

There is nothing to sign up for — no application, no enrollment window, no card. Your doctor submits a prior authorization to a CMS central processor, and you receive a confirmation letter. Access to the Medicare GLP-1 Bridge is settled between your doctor and Medicare, so your only tasks are the conversation and your Medicare ID.

7. What if my Medicare GLP-1 Bridge prior authorization is denied?

Start by asking your doctor whether the denial was a documentation gap — a missing BMI reading or qualifying condition — because prescribers can file a new request. Then call 1-800-MEDICARE, since the Bridge bypasses your plan’s appeals desk. If you still do not qualify after that, cash-pay manufacturer programs are worth pricing out.

My Bottom Line

So, does Medicare cover weight loss drugs? The honest version: the old exclusion still stands, but through the end of 2027 the Medicare GLP-1 Bridge gives three drugs a $50 path for anyone who clears all four requirements. Temporary, narrow, and genuinely useful.

The best next click is the page that matches the bottle in front of you. If the prescription is semaglutide for weight loss, start with the Wegovy answer. If the confusion is the brand your neighbor takes for diabetes, the Ozempic page untangles it. If you start one of these drugs, keep my foods to eat on GLP-1 guide nearby.

Resources

The primary sources behind this guide:

• CMS: Medicare GLP-1 Bridge
• Medicare official fact sheet (Product No. 12234): GLP-1 drugs for $50 a month
• CMS launch press release (July 1, 2026)
• Medicare.gov: GLP-1 Bridge eligibility information
• KFF: The BALANCE model and GLP-1s in Medicare and Medicaid
• AARP: The $50 GLP-1 copay program explained